Innate immunity at the molecular level

Intuition [Beginner]

Your body is under constant assault. Bacteria, viruses, fungi, and parasites try to enter every time you breathe, eat, or get a cut. The first line of defence is the innate immune system — a rapid-response force that attacks anything recognisable as foreign, without needing prior exposure or learning.

The innate system recognises broad molecular patterns shared by entire classes of microbes: the lipopolysaccharide in Gram-negative bacterial walls, the double-stranded RNA produced during viral replication, the unmethylated DNA sequences common in bacteria but rare in vertebrates. These patterns are conserved because they are essential for microbial survival — the pathogen cannot easily mutate them away without killing itself.

These patterns are detected by proteins called pattern recognition receptors, or PRRs, located on and inside sentinel cells such as macrophages and dendritic cells. When a PRR binds its target molecule, it triggers an intracellular alarm cascade that activates the cell within thirty minutes.

The activated cell secretes cytokines — chemical messengers that recruit and activate other immune cells. Phagocytes (neutrophils and macrophages) literally swallow bacteria and digest them in membrane-bound compartments. Complement proteins in the blood coat pathogens and punch holes in their membranes. Natural killer cells detect and destroy host cells that viruses have hijacked.

The innate response is fast (minutes to hours) but imprecise. It buys time for the slower but highly specific adaptive immune system (T cells and B cells) to mount a targeted response over days. The innate system also serves as gatekeeper: it provides the activation signals that tell the adaptive system whether and how to respond.

Why does this concept exist? Innate immunity solves the recognition problem by detecting a small set of conserved molecular signatures that reliably signal microbial presence — a computational shortcut that avoids the need to catalogue every possible pathogen individually.

Visual [Beginner]

A macrophage patrols tissue with Toll-like receptors studding its surface. When a Gram-negative bacterium sheds lipopolysaccharide, the LPS-binding protein in plasma picks it up and hands it to CD14 on the macrophage, which presents LPS to the TLR4/MD-2 complex. TLR4 dimerises, and the signal cascades through a chain of intracellular kinases (IRAK4, IRAK1, TRAF6, TAK1) to activate NF-kB, which enters the nucleus and turns on cytokine genes. Outside the cell, complement proteins deposit on the bacterial surface in an amplifying cascade, and neutrophils arrive to engulf the opsonised bacteria.

The feature to notice is amplification: one LPS molecule binding one TLR triggers production of thousands of cytokine molecules, and each complement protein that deposits creates an enzyme that deposits many more. The innate system is a molecular amplifier.

Worked example [Beginner]

Trace the detection of bacterial LPS by TLR4 on a macrophage — the pathway that drives septic shock when LPS floods the bloodstream.

Step 1. A Gram-negative bacterium enters a skin wound. It sheds lipopolysaccharide (LPS) into surrounding tissue. Within minutes, LPS-binding protein (LBP) in the blood picks up free LPS molecules and transfers them to CD14 on the macrophage surface.

Step 2. CD14 presents LPS to the TLR4/MD-2 complex. Two TLR4 molecules dimerise around the LPS, bringing their intracellular TIR domains together. This dimerisation is the molecular switch that turns on downstream signaling.

Step 3. The paired TIR domains recruit the adaptor protein MyD88, which in turn recruits the kinase IRAK4. IRAK4 phosphorylates IRAK1, which activates the ubiquitin ligase TRAF6. TRAF6 builds ubiquitin chains that activate the TAK1 kinase complex.

Step 4. TAK1 activates the IKK complex. IKK phosphorylates the inhibitor protein IkB, marking it for degradation by the proteasome. With IkB removed, the transcription factor NF-kB is free to enter the nucleus.

Step 5. Within 30 minutes of initial LPS contact, the macrophage transcribes and secretes the cytokines TNF-alpha and IL-6. TNF-alpha causes local blood vessels to dilate and become leaky, allowing neutrophils to exit the bloodstream. IL-6 reaches the liver and stimulates acute-phase protein production.

Step 6. Complement proteins in plasma coat the bacteria. Neutrophils arriving at the site engulf the opsonised bacteria and destroy them with reactive oxygen species and lysosomal enzymes.

What this tells us: a single molecular pattern (LPS) detected by a single receptor type (TLR4) triggers a coordinated multi-component defence within thirty minutes — inflammation, phagocyte recruitment, complement activation, and systemic acute-phase response — all before adaptive immunity has begun its slower, antigen-specific response.

Check your understanding [Beginner]

Formal definition [Intermediate+]

Innate immunity is the first-line defence system that provides immediate protection against pathogens through physical barriers, germline-encoded pattern recognition, phagocytosis, inflammation, complement activation, and cytotoxic killing. It operates within minutes using receptors encoded in the germline (not generated by somatic recombination as in adaptive immunity) and does not produce immunological memory.

Pattern recognition receptors

PRRs are germline-encoded receptors that recognise pathogen-associated molecular patterns (PAMPs) — conserved molecular structures shared by broad classes of microbes — and damage-associated molecular patterns (DAMPs) — host molecules released or modified during tissue damage.

Toll-like receptors (TLRs): The best-characterised PRR family, with ten functional TLRs in humans. Each TLR has an extracellular leucine-rich repeat (LRR) domain for ligand binding, a single transmembrane helix, and an intracellular TIR (Toll/IL-1 receptor) domain for downstream signaling.

TLR	Ligand (PAMP)	Source
TLR1/2	Triacyl lipopeptides	Bacteria
TLR2	Peptidoglycan, lipoteichoic acid	Gram-positive bacteria
TLR3	Double-stranded RNA	Viruses
TLR4	LPS (lipopolysaccharide)	Gram-negative bacteria
TLR5	Flagellin	Motile bacteria
TLR7/8	Single-stranded RNA	Viruses
TLR9	Unmethylated CpG DNA	Bacteria, viruses
TLR10	Unknown (putative inhibitory)	—

NOD-like receptors (NLRs): Cytoplasmic sensors with a central nucleotide-binding and oligomerisation (NACHT) domain, C-terminal leucine-rich repeats, and an N-terminal effector domain. Key members include NOD1 and NOD2 (which detect bacterial peptidoglycan fragments in the cytosol — NOD2 mutations are associated with Crohn disease) and NLRP3, which forms the inflammasome upon sensing diverse danger signals.

RIG-I-like receptors (RLRs): Cytoplasmic RNA helicases that detect viral RNA. RIG-I senses short 5-prime-triphosphate RNA (a hallmark of viral replication intermediates); MDA5 detects long double-stranded RNA. Both signal through the adaptor MAVS on the mitochondrial outer membrane.

C-type lectin receptors (CLRs): Detect fungal carbohydrate patterns (mannans, beta-glucans). Dectin-1 is the best-characterised CLR, recognizing beta-1,3-glucan in fungal cell walls.

Complement system

The complement system is a cascade of approximately 30 plasma proteins that opsonise pathogens, recruit phagocytes, and directly lyse bacteria via the membrane attack complex (MAC). Three activation pathways converge on a central amplification node:

1. Classical pathway: Antibody-antigen complexes bind C1q, initiating the cascade through C1r and C1s. This pathway links innate and adaptive immunity.

2. Lectin pathway: Mannose-binding lectin (MBL) binds mannose residues on pathogen surfaces, activating MBL-associated serine proteases (MASPs). Functionally analogous to the classical pathway but antibody-independent.

3. Alternative pathway: C3 spontaneously hydrolyses at a low rate ("tickover"). On pathogen surfaces lacking regulatory proteins, this initiates an amplification loop. Evolutionarily the most ancient pathway.

All three converge on C3 convertase, which cleaves C3 into C3a (an anaphylatoxin that triggers mast-cell degranulation and inflammation) and C3b (an opsonin that coats the pathogen surface for phagocytosis). The C3b deposited by any pathway can join the existing C3 convertase to form C5 convertase, which cleaves C5 into C5a (anaphylatoxin) and C5b. C5b recruits C6, C7, C8, and multiple C9 molecules to form the pore-forming membrane attack complex (MAC) in the pathogen membrane.

Key cytokines of innate immunity

• TNF-alpha: Induces inflammation, fever, and endothelial activation. Excess TNF causes septic shock through systemic vasodilation and vascular leak.
• IL-1beta: Produced upon inflammasome activation. Induces fever and T-cell activation. Targeted therapeutically by anakinra (IL-1 receptor antagonist).
• IL-6: Drives the acute-phase response in the liver (CRP, fibrinogen production), B-cell differentiation, and fever.
• Type I interferons (IFN-alpha, IFN-beta): Antiviral cytokines produced by virus-infected cells. Induce an antiviral state in neighbouring cells by upregulating PKR, OAS, and Mx proteins.
• IL-12: Produced by dendritic cells and macrophages; drives Th1 differentiation and NK-cell activation.

Counterexamples to common slips

• Innate immunity is non-specific. It is specific for conserved molecular patterns (PAMPs and DAMPs) through germline-encoded receptors — just not antigen-specific like adaptive immunity. TLR4 does not bind flagellin; TLR5 does not bind LPS. The specificity is real but directed at molecular classes, not individual antigens.
• Only immune cells express TLRs. Epithelial cells, endothelial cells, keratinocytes, and neurons all express TLRs and contribute to innate defence at barrier surfaces.
• Complement only opsonises pathogens. The terminal complement complex (C5b-9, the MAC) forms transmembrane pores that directly lyse Gram-negative bacteria. C3a and C5a are anaphylatoxins that recruit and activate neutrophils independently of opsonisation.

Key theorem with proof [Intermediate+]

Theorem (Alternative-pathway complement amplification). Consider the alternative pathway of complement activation on a surface $S$ lacking regulatory proteins (Factor H, Factor I). Let $C(t)$ denote the surface density of the C3 convertase C3bBb at time $t$, $[\text{C3}{]}_0$ the plasma concentration of complement component C3, $k_{\text{cat}}$ the catalytic turnover number of C3bBb for cleaving C3, $k_f$ the effective rate constant for new convertase formation from each deposited C3b molecule, and $k_d$ the first-order dissociation rate of surface-bound C3bBb. The convertase density obeys

$$\frac{dC}{dt}=\left(k_f{k}_{\text{cat}}[\text{C3}{]}_0-k_d\right)C=\lambda C,\lambda :=k_f{k}_{\text{cat}}[\text{C3}{]}_0-k_d.$$

On activator surfaces (pathogens lacking Factor H) where $\lambda >0$, the convertase grows exponentially: $C(t)=C_0{e}^{\lambda t}$. On host surfaces expressing Factor H and Factor I, the effective $k_d$ increases by two orders of magnitude, making $\lambda <0$ and causing rapid decay of deposited C3b.

Proof. Each convertase molecule at time $t$ cleaves C3 at rate $k_{\text{cat}}[\text{C3}{]}_0$, producing C3a and C3b. The newly generated C3b deposits on the surface. Of the deposited C3b, a fraction characterised by the effective rate constant $k_f$ successfully recruits Factor B, undergoes cleavage by Factor D, and forms a new C3bBb convertase before being inactivated by Factor I. (On activator surfaces, Factor H is absent, Factor I cannot efficiently degrade C3b, and $k_f$ is high.)

The rate of new convertase formation is therefore $k_f\cdot k_{\text{cat}}\cdot C(t)\cdot [\text{C3}{]}_0$. Each convertase molecule also dissociates (the Bb fragment detaches from C3b) at rate $k_d$. The net rate of change is:

$$\frac{dC}{dt}=k_f{k}_{\text{cat}}[\text{C3}{]}_0\cdot C(t)-k_d\cdot C(t)=\lambda C(t).$$

This is a linear first-order ODE with solution $C(t)=C_0{e}^{\lambda t}$, where $C_0$ is the initial convertase density seeded by spontaneous C3 tickover (the slow hydrolysis $\text{C3}+{\text{H}}_2\text{O}\to {\text{C3(H}}_2\text{O)}$ at rate $k_H[\text{C3}{]}_0$, followed by fluid-phase convertase formation and C3b deposition). The exponential growth is valid during the early phase when $[\text{C3}{]}_0$ is approximately constant (i.e., before significant C3 depletion from plasma).

On host cells, Factor H binds deposited C3b and recruits Factor I, which cleaves C3b into inactive iC3b. This increases the effective $k_d$ from approximately $0.5{\text{ min}}^{-1}$ on activator surfaces to approximately $50{\text{ min}}^{-1}$ on host surfaces, ensuring $\lambda <0$ and rapid clearance of any accidentally deposited C3b. $\square$

Numerical estimate. With physiological values $k_f\approx 0.1$, $k_{\text{cat}}\approx 2{\text{ min}}^{-1}$, $[\text{C3}{]}_0\approx 6.5\mu \text{M}$, and $k_d\approx 0.5{\text{ min}}^{-1}$ on an activator surface: $\lambda =0.1\times 2\times 6.5-0.5=1.3-0.5=0.8{\text{ min}}^{-1}$. The doubling time is $\ln 2/0.8\approx 0.87\text{ min}$ (52 seconds). Starting from a single tickover event ($C_0\approx 1$ convertase), after 10 minutes: $C(10)\approx e^8\approx 3000$ convertases, each cleaving C3 at 2 per minute — an amplification exceeding $10^6$ relative to the initial tickover rate.

Bridge. The complement amplification factor generalises the principle that enzyme cascades convert small initial signals into large outputs through catalytic positive feedback — this is exactly the same logic that operates in blood coagulation and the apoptotic caspase cascade. The foundational reason complement can discriminate self from non-self at the molecular level is that host cells express regulatory proteins (Factor H, CD55, CD59) that tip the kinetic balance toward decay, while pathogen surfaces lack these regulators and permit exponential amplification. This pattern appears again in 17.09.02 pending, where the Hodgkin-Huxley sodium-channel positive feedback converts a small voltage perturbation into a full action potential — the same exponential-growth mechanism operating in a different molecular substrate. Putting these together, the complement system and the action potential are both instances of threshold-gated biological amplifiers, and the bridge is between enzymatic amplification at the protein scale and electrical amplification at the membrane scale.

Exercises [Intermediate+]

Pattern recognition receptors and downstream signaling [Master]

The four families of pattern recognition receptors — TLRs, NLRs, RLRs, and CLRs — share a common architectural principle: an extracellular or cytosolic ligand-binding domain, a dimerisation or oligomerisation interface, and an intracellular signaling domain that recruits downstream adaptors. The specificity of the innate response arises from two variables: which receptor is engaged, and in which cell type the engagement occurs.

TLR signaling architecture. All TLRs except TLR3 signal through the adaptor MyD88, which recruits IRAK4 and IRAK1 via death-domain interactions. TLR3 and TLR4 also signal through the adaptor TRIF (TIR-domain-containing adaptor inducing interferon-beta), which activates IRF3 (interferon regulatory factor 3) and induces type I interferon transcription. TLR4 is unique in using both adaptors: MyD88-dependent signaling from the plasma membrane (via the bridging adaptor TIRAP/Mal) produces early NF-kB activation and inflammatory cytokines, while TRIF-dependent signaling from endosomes (via the bridging adaptor TRAM) produces late NF-kB activation plus IRF3-mediated interferon-beta production ^{[Medzhitov and Janeway 2002]}. This temporal compartmentalisation gives TLR4 two distinct signaling outputs from a single receptor: an early inflammatory wave (minutes) and a late antiviral wave (hours).

NF-kB activation kinetics. The NF-kB/IkB system functions as a negative-feedback oscillator. NF-kB (typically the p50/p65 heterodimer) is held inactive in the cytoplasm by IkB-alpha, which masks the nuclear localisation signal. IKK-mediated phosphorylation of IkB-alpha triggers its proteasomal degradation, releasing NF-kB to enter the nucleus and activate target genes. Among those target genes is IkB-alpha itself, creating a negative-feedback loop: NF-kB induces IkB-alpha resynthesis, the newly synthesised IkB-alpha re-enters the nucleus, binds NF-kB, and exports it back to the cytoplasm. In single-cell imaging experiments (Nelson et al. 2004 Science 306, 704-708), NF-kB nuclear localisation oscillates with a period of approximately 100 minutes under sustained TNF-alpha stimulation, with each oscillatory pulse driving a distinct wave of gene transcription — early genes (inflammatory cytokines) are activated by the first pulse, while late genes (negative regulators, anti-apoptotic proteins) require sustained oscillations.

NOD1 and NOD2 signaling. Unlike TLRs (which survey the extracellular space and endosomes), NOD1 and NOD2 detect bacterial peptidoglycan fragments that reach the cytosol — either through bacterial secretion systems, pore-forming toxins, or endosomal escape. NOD1 recognises meso-diaminopimelic acid (found primarily in Gram-negative bacteria), while NOD2 detects muramyl dipeptide (present in both Gram-positive and Gram-negative peptidoglycan). Both signal through the adaptor RIP2 (receptor-interacting protein 2), which activates TAK1 and the downstream NF-kB and MAPK pathways using the same enzymatic machinery as TLR signaling. Crohn disease-associated NOD2 frameshift mutations (particularly L1007fs) produce a truncated protein that cannot detect muramyl dipeptide, impairing innate immune detection of intestinal bacteria and predisposing to dysregulated inflammation in the gut.

Cell-type specificity. The same TLR4 signal produces different outputs depending on the cell type. In macrophages, TLR4 activation produces TNF-alpha and IL-6 (inflammatory effector functions). In dendritic cells, TLR4 upregulates co-stimulatory molecules CD80 and CD86, which are required for T-cell activation in the adaptive immune response — this is Janeway's insight that innate immunity provides the "instruction" for adaptive immunity ^{[Janeway 1989]}. In endothelial cells, TLR4 induces E-selectin and ICAM-1 (leukocyte adhesion molecules that recruit immune cells to inflamed tissue). In neurons, TLR4 activation can contribute to neuroinflammation and pain sensitization.

The complement system: three pathways converge on membrane attack [Master]

The complement system comprises approximately 30 plasma proteins that together constitute a proteolytic cascade analogous in architecture to the blood coagulation cascade. Each protease in the cascade activates the next by limited proteolysis, producing signal amplification at every step. The three activation pathways differ in how they initiate but converge at C3 convertase formation.

Classical pathway. C1q (a hexameric pattern-recognition molecule with six globular heads on collagen-like stalks) binds antibody-antigen complexes, C-reactive protein bound to bacterial surfaces, or directly to certain microbial surfaces. Binding induces a conformational change in the associated serine proteases C1r and C1s. Activated C1s cleaves C4 into C4a (released) and C4b (deposits on the target surface near the activation site). C4b binds C2, which is then cleaved by C1s into C2a (released) and C2b. The resulting C4bC2b complex is the classical-pathway C3 convertase, which cleaves C3 into C3a and C3b.

Lectin pathway. Mannose-binding lectin (MBL) and ficolins scan carbohydrate patterns on microbial surfaces. Upon binding, MBL-associated serine proteases (MASP-1 and MASP-2, homologues of C1r and C1s) are activated. MASP-2 cleaves C4 and C2 to form the same C4bC2b C3 convertase as the classical pathway. The lectin pathway is antibody-independent and provides innate immune defence before the adaptive response has generated specific antibodies.

Alternative pathway and amplification. C3 spontaneously hydrolyses at a slow rate ($k_H\approx 10^{-6}{\text{ s}}^{-1}$), producing C3(H2O) in the fluid phase. This "tickover" molecule binds Factor B, which is cleaved by Factor D to form C3(H2O)Bb — a fluid-phase C3 convertase that deposits C3b on any nearby surface. On host cells, Factor H (which recognises host-surface polyanions such as sialic acid) binds the deposited C3b and recruits Factor I to degrade it. On pathogen surfaces (which lack these polyanion markers), Factor H does not bind, C3b persists, and the deposited C3b recruits Factor B. Factor D cleaves Factor B to form C3bBb — the alternative-pathway C3 convertase, stabilised by properdin. This convertase cleaves more C3, depositing more C3b, which forms more convertase: the positive-feedback amplification loop described by the complement amplification theorem proved above.

Membrane attack complex. When C3b joins an existing C3 convertase, the resulting C5 convertase (either C4bC2bC3b in the classical/lectin pathway or C3bBbC3b in the alternative pathway) cleaves C5 into C5a and C5b. C5b initiates a sequential assembly: C5b-C6-C7 inserts into the lipid bilayer, C8 stabilises the insertion, and up to 18 molecules of C9 polymerise to form a cylindrical pore approximately 10 nm in diameter. This MAC (C5b-9) pore disrupts the osmotic integrity of Gram-negative bacteria and enveloped viruses, causing lysis. Gram-positive bacteria are resistant to MAC because their thick peptidoglycan layer prevents MAC insertion into the cytoplasmic membrane.

Regulation. Host cells are protected by membrane-bound regulators: CD55 (decay-accelerating factor) accelerates dissociation of C3 convertases; CD59 blocks C9 polymerisation and prevents MAC formation; CR1 (complement receptor 1) acts as a co-factor for Factor I. Soluble regulators include Factor H (alternative pathway), C4b-binding protein (classical/lectin pathway), and C1 inhibitor (C1, MASPs). Deficiency in any regulator produces disease: CD59 deficiency causes PNH; Factor H mutations cause aHUS; C1 inhibitor deficiency causes hereditary angioedema.

Therapeutic complement inhibition. Eculizumab (anti-C5 monoclonal antibody) blocks C5 cleavage, preventing MAC formation. Approved for PNH (2007), aHUS (2011), and generalised myasthenia gravis (2017). Ravulizumab is a long-acting C5 inhibitor dosed every 8 weeks (versus every 2 weeks for eculizumab). Pegcetacoplan (anti-C3) blocks all three pathways at the central amplification node, providing an alternative for PNH patients with residual anaemia on C5 inhibitors. The clinical success of complement inhibitors validates the amplification theorem: blocking a single step in the cascade is sufficient to prevent downstream tissue damage.

Inflammasomes and pyroptotic cell death [Master]

Inflammasomes are multi-protein complexes that assemble in the cytosol in response to intracellular danger signals. Their assembly activates caspase-1, which processes the pro-inflammatory cytokines pro-IL-1beta and pro-IL-18 into their active forms and triggers pyroptosis — an inflammatory form of programmed cell death. The inflammasome is the innate immune system's mechanism for responding to intracellular threats that TLRs cannot detect.

NLRP3 inflammasome. NLRP3 is the most studied inflammasome sensor, activated by a remarkably diverse set of stimuli that share a common upstream mechanism: potassium efflux from the cytosol. Activators include extracellular ATP (acting through the P2X7 ion channel), uric acid crystals (gout), cholesterol crystals (atherosclerosis), amyloid-beta aggregates (Alzheimer disease), silica particles (silicosis), asbestos, and pore-forming bacterial toxins. NLRP3 activation requires two signals: (1) a priming signal (typically TLR engagement or TNF-alpha stimulation) that upregulates NLRP3 and pro-IL-1beta transcription via NF-kB; and (2) an activation signal (any of the potassium-efflux-inducing stimuli listed above) that triggers NLRP3 oligomerisation.

Upon activation, NLRP3 oligomerises through its NACHT domain, exposing its N-terminal pyrin domain (PYD), which recruits the adaptor ASC (apoptosis-associated speck-like protein containing a CARD) via homotypic PYD-PYD interactions. ASC in turn recruits pro-caspase-1 through CARD-CARD interactions, forming a large filamentous structure (the "ASC speck") visible by fluorescence microscopy. The high local concentration of pro-caspase-1 drives autocatalytic activation: pro-caspase-1 cleaves itself into active caspase-1, a heterotetramer of two p20 and two p10 subunits.

Active caspase-1 has two substrates relevant to innate defence. First, it cleaves pro-IL-1beta (31 kDa) into mature IL-1beta (17 kDa), which is secreted through gasdermin D pores and activates IL-1 receptors on neighbouring cells, producing fever, inflammation, and further immune-cell recruitment. Second, it cleaves gasdermin D (GSDMD) at a site in the middle of the protein, releasing the N-terminal fragment (GSDMD-NT), which inserts into the plasma membrane and oligomerises into pores approximately 10-14 nm in diameter. These pores are the effector mechanism of pyroptosis: they allow IL-1beta and IL-18 egress, disrupt cellular ion gradients, and cause osmotic lysis of the infected cell. Pyroptosis eliminates the intracellular niche that intracellular pathogens (Salmonella, Listeria, Mycobacterium) require for replication.

AIM2 inflammasome. AIM2 (absent in melanoma 2) is a cytosolic dsDNA sensor that detects DNA longer than approximately 80 base pairs without sequence specificity. Upon binding dsDNA through its HIN200 domain, AIM2 oligomerises and recruits ASC via PYD-PYD interactions, forming an ASC speck and activating caspase-1 through the same mechanism as NLRP3. AIM2 detects viral DNA (poxviruses, herpesviruses), intracellular bacterial DNA, and self-DNA that has leaked from the nucleus or mitochondria during cellular damage. In systemic lupus erythematosus, defective clearance of self-DNA leads to chronic AIM2 activation and contributes to the type I interferon signature characteristic of the disease.

NLRC4 inflammasome. NLRC4 detects bacterial flagellin and type III secretion system (T3SS) components indirectly through the NAIP (NLR family apoptosis inhibitory protein) sensors. Human NAIP detects different bacterial proteins (flagellin via NAIP, T3SS needle protein via NAIP) and then activates NLRC4 by inducing its oligomerisation. NLRC4 contains a CARD domain and can recruit caspase-1 directly without requiring ASC (though ASC enhances the response). NLRC4 activation is especially important for defence against Salmonella, Shigella, and Legionella — intracellular bacteria that use flagella or secretion systems during infection.

Non-canonical inflammasome. Caspase-4 and caspase-5 (in humans; caspase-11 in mice) directly bind intracellular LPS from Gram-negative bacteria that have escaped the phagosome. Upon LPS binding, these caspases oligomerise and cleave gasdermin D, triggering pyroptosis independently of the canonical NLRP3/ASC/caspase-1 pathway. Non-canonical activation also induces NLRP3 activation secondarily through potassium efflux from gasdermin D pores, linking the two pathways.

Autoinflammatory diseases. Gain-of-function mutations in inflammasome components produce periodic fever syndromes characterised by recurrent episodes of systemic inflammation without infection. NLRP3 mutations cause CAPS (cryopyrin-associated periodic syndromes), treated with IL-1 blockade (anakinra, canakinumab, rilonacept). MEFV mutations (affecting the protein pyrin, which forms a distinct inflammasome sensing Rho GTPase inactivation by bacterial toxins) cause familial Mediterranean fever (FMF), treated with colchicine. The CANTOS trial (Ridker et al. 2017 N. Engl. J. Med. 377, 1119-1131) demonstrated that canakinumab reduces cardiovascular events in patients with elevated CRP, establishing IL-1beta as a therapeutic target in atherosclerosis — an inflammatory disease driven in part by NLRP3 activation by cholesterol crystals.

Interferon signaling and the antiviral state [Master]

Type I interferons (IFN-alpha, comprising 13 subtypes, and IFN-beta) are the master cytokines of antiviral defence. They are produced within hours of viral infection and induce an antiviral state in neighbouring cells that blocks viral replication for days. The interferon system is the innate immune analogue of the adaptive immune system's antibody response: rapid, broad-spectrum, and critical for controlling infection before the adaptive response matures.

cGAS-STING pathway. Cyclic GMP-AMP synthase (cGAS) is a cytosolic enzyme that detects double-stranded DNA in the cytosol — a hallmark of DNA virus infection, retroviral reverse transcription intermediates, or intracellular bacterial DNA. Upon binding dsDNA, cGAS catalyses the synthesis of 2-prime-3-prime cyclic GMP-AMP (cGAMP), a second messenger that binds and activates STING (stimulator of interferon genes) on the endoplasmic reticulum membrane. Activated STING translocates to the Golgi, recruits TBK1 (TANK-binding kinase 1), and TBK1 phosphorylates IRF3 (interferon regulatory factor 3). Phosphorylated IRF3 dimerises, enters the nucleus, and binds the interferon-beta promoter. The cGAS-STING pathway was discovered by Zhijian "James" Chen's laboratory (Sun et al. 2013 Science 339, 786-791; Wu et al. 2013 Science 339, 826-830) and is now recognised as the primary cytosolic DNA-sensing pathway for type I interferon induction.

RIG-I-MAVS pathway. Retinoic acid-inducible gene I (RIG-I) detects viral RNA bearing a 5-prime-triphosphate moiety — a signature of viral RNA polymerase activity absent from mature host mRNA (which is capped at the 5-prime end). MDA5 detects long double-stranded RNA (a replication intermediate of many RNA viruses). Both RIG-I and MDA5 signal through the adaptor MAVS (mitochondrial antiviral signaling protein) on the outer mitochondrial membrane, the mitochondrial-associated ER membrane, and peroxisomes. MAVS recruits TBK1 and IKK-epsilon, which phosphorylate IRF3 and IRF7, inducing type I interferon transcription. The subcellular localisation of MAVS on mitochondria integrates antiviral signaling with the cell's metabolic state — mitochondrial damage (detected by NLRP3) and viral RNA detection (detected by RIG-I) are co-ordinated at the same organelle.

JAK-STAT signaling. Secreted type I interferons bind the heterodimeric IFNAR receptor (IFNAR1/IFNAR2) on the surface of the producing cell (autocrine) and neighbouring cells (paracrine). Receptor engagement activates the receptor-associated kinases JAK1 and TYK2, which phosphorylate STAT1 and STAT2. Phosphorylated STAT1-STAT2 heterodimers associate with IRF9 to form the ISGF3 (interferon-stimulated gene factor 3) complex, which translocates to the nucleus and binds ISRE (interferon-stimulated response element) sequences in the promoters of hundreds of interferon-stimulated genes (ISGs). The JAK-STAT pathway is a two-step amplifier: the first step (viral detection) produces a small amount of IFN-beta; the second step (IFN-beta signaling through IFNAR) induces a large panel of ISGs including IRF7, which then drives massive IFN-alpha production — a positive-feedback loop that amplifies the antiviral signal across the tissue.

Interferon-stimulated gene products. Three ISG effector mechanisms are particularly well-characterised. (1) PKR (protein kinase R) binds viral double-stranded RNA and phosphorylates the translation initiation factor eIF2alpha, shutting down cap-dependent translation in the infected cell and blocking viral protein synthesis. (2) OAS (2-prime-5-prime oligoadenylate synthase) produces 2-prime-5-prime oligoadenylates that activate RNase L, which degrades single-stranded RNA (both viral and cellular), destroying the viral genome and inducing apoptosis of the infected cell. (3) Mx proteins (MxA, MxB) are dynamin-like GTPases that trap viral nucleocapsids and prevent their trafficking to the site of replication. Together, these ISGs create an intracellular environment hostile to virtually all viruses.

Viral evasion strategies. The intensity of selection pressure imposed by the interferon system is evidenced by the extraordinary diversity of viral evasion mechanisms. Influenza NS1 protein binds dsRNA (preventing RIG-I and PKR activation) and blocks RIG-I ubiquitination. Vaccinia virus E3L protein sequesters dsRNA. Hepatitis C virus NS3/4A protease cleaves MAVS and TRIF, disconnecting the viral-RNA-sensing pathway from downstream signaling. Kaposi sarcoma herpesvirus (KSHV) ORF52 inhibits cGAS enzymatic activity directly. Herpes simplex virus ICP34.5 recruits protein phosphatase 1 to dephosphorylate eIF2alpha, reversing PKR-mediated translation shutoff. These evasion mechanisms are essential for viral pathogenicity: mutant viruses lacking evasion genes are attenuated and serve as experimental vaccine candidates.

Synthesis. The innate immune system is the foundational reason that vertebrates survive long enough for adaptive immunity to develop: the four molecular subsystems examined here — pattern recognition receptor signaling, complement amplification, inflammasome-mediated pyroptosis, and type I interferon antiviral defence — together constitute a multi-layered detection-and-response network operating on timescales from seconds (complement amplification with doubling time under one minute) to hours (the full interferon-stimulated antiviral state). The central insight is that each subsystem uses a conserved molecular trigger to initiate a catalytic cascade, and this is exactly the design principle that enables speed. Putting these together, the four subsystems are not independent: NF-kB activated by TLR signaling upregulates both NLRP3 and pro-IL-1beta, priming the inflammasome; complement anaphylatoxins C3a and C5a recruit and activate TLR-bearing phagocytes; type I interferon modulates TLR expression levels. The bridge is between the molecular enzymology of each cascade and the organismal-level integrated immune response that emerges from their coupling. The pattern recognition theory ^{[Janeway 1989]} provides the unifying framework: innate immunity detects a limited repertoire of conserved microbial signatures and converts each detection event into a stereotyped amplification cascade whose output is matched to the class of threat detected.

Full proof set [Master]

Proposition (Host discrimination by Factor H). On a surface expressing Factor H at effective surface density ${\rho }_H$, the effective convertase decay rate exceeds the spontaneous dissociation rate by an amount proportional to ${\rho }_H$. If Factor H catalyses Factor I-mediated inactivation of C3b at rate $k_{FH}$, then $k_d^{\text{eff}}=k_d^0+k_{FH}{\rho }_H$, and the surface is protected from complement amplification whenever

$${\rho }_H>\frac{k_f{k}_{\text{cat}}[\text{C3}{]}_0-k_d^0}{k_{FH}}.$$

Proof. Factor H binds deposited C3b and recruits Factor I, which cleaves the alpha-prime chain of C3b at two sites, generating iC3b. iC3b cannot bind Factor B and therefore cannot form C3bBb convertase. The rate of convertase inactivation by this pathway is $k_{FH}{\rho }_{H}C(t)$, where ${\rho }_H$ is the Factor H surface density (assumed constant, as Factor H is abundant in plasma at approximately 500 micrograms per millilitre). Adding this to the spontaneous dissociation rate $k_d^{0}C(t)$ gives:

$$\frac{dC}{dt}=k_f{k}_{\text{cat}}[\text{C3}{]}_0\cdot C(t)-\left(k_d^0+k_{FH}{\rho }_H\right)C(t)=\left({\lambda }_0-k_{FH}{\rho }_H\right)C(t),$$

where ${\lambda }_0=k_f{k}_{\text{cat}}[\text{C3}{]}_0-k_d^0$ is the net growth rate in the absence of Factor H. The convertase decays ($dC/dt<0$) whenever ${\rho }_H>{\lambda }_0/k_{FH}$, establishing the threshold for host protection. $\square$

This proposition quantifies the central complement-discrimination mechanism: host surfaces are protected not by an absolute barrier but by a kinetic threshold set by Factor H density. Pathogen surfaces that fail to recruit Factor H fall below this threshold and permit exponential amplification. Loss-of-function mutations in Factor H reduce ${\rho }_H$ below the threshold on renal endothelial cells, causing the uncontrolled alternative-pathway activation that characterises aHUS.

Connections [Master]

• Action potential — ionic basis 17.09.02 pending. Both innate immune signaling and action-potential generation are transmembrane signal-transduction events that use positive feedback to amplify small inputs into large, stereotyped outputs. The complement amplification theorem's exponential growth parallels the sodium-channel regenerative upstroke; both systems convert analog inputs into all-or-none responses through threshold-gated switching. The membrane-biophysics infrastructure (ion gradients, transmembrane proteins, lipid bilayer barriers) is shared between immune-cell activation and neuronal excitability.

• Canonical ensemble 11.04.01 pending. The receptor-ligand binding equilibria that govern PRR-PAMP interactions — the dissociation constant $K_d$ of TLR4 for LPS, the affinity of C3b for pathogen versus host surfaces — derive from the canonical-ensemble Boltzmann factor. The fraction of TLR4 receptors occupied at a given LPS concentration follows the Langmuir isotherm $f=[\text{L}]/(K_d+[\text{L}])$, which is the single-ligand limit of the partition-function machinery 11.04.01 pending applied to protein-ligand interactions.

• Hardy-Weinberg equilibrium 19.02.01 pending. Innate immune gene polymorphisms (TLR variants, complement Factor H mutations, NLRP3 gain-of-function alleles) segregate in human populations at frequencies predictable from Hardy-Weinberg proportions. Disease-association studies of sepsis susceptibility, malaria resistance mediated by complement receptor variants, and hereditary autoinflammatory syndromes all begin from the Hardy-Weinberg baseline. Intense selective pressure from infectious diseases drives deviations from that equilibrium at innate-immunity loci — producing some of the strongest signatures of positive selection in the human genome.

Historical and philosophical context [Master]

The concept of innate immunity dates to Ilya Metchnikoff's 1882 observation that starfish larval cells surrounded and engulfed rose thorns inserted into the larvae — the discovery of phagocytosis and the founding observation of cellular immunology ^{[Metchnikoff 1882]}. Metchnikoff's 1901 monograph argued that phagocytes were the primary defence against infection, competing with Ehrlich's humoral-immunity theory; both were recognised in the 1908 Nobel Prize in Physiology or Medicine.

The modern understanding of innate immunity was revolutionised by Charles Janeway's 1989 Cold Spring Harbor symposium contribution, which proposed that the innate immune system provides the "instructions" for adaptive immunity through germline-encoded pattern recognition receptors detecting conserved microbial structures ^{[Janeway 1989]}. This PAMP/PRR hypothesis predicted the existence of a receptor family that had not yet been identified in mammals.

Jules Hoffmann's laboratory demonstrated in 1996 that the Drosophila Toll pathway (previously known for dorsal-ventral patterning in embryogenesis) also mediates antifungal defence in adult flies ^{[Hoffmann 1996]}, establishing that innate immunity is ancient and conserved across animals. Bruce Beutler identified the mouse Lps mutation — which abolished LPS responsiveness and caused susceptibility to Gram-negative sepsis — as a loss-of-function allele of TLR4 in 1998 ^{[Beutler 1998]}, providing the mammalian confirmation of the PRR hypothesis. Ruslan Medzhitov and Janeway cloned the first human Toll-like receptor in 1997 and demonstrated that it activates NF-kB and adaptive immunity ^{[Medzhitov 1997]}. Hoffmann and Beutler shared the 2011 Nobel Prize in Physiology or Medicine; Janeway had died in 2003 and could not share it.

Bibliography [Master]

@article{Janeway1989,
  author = {Janeway, Charles A.},
  title = {Approaching the asymptote? Evolution and revolution in immunology},
  journal = {Cold Spring Harb. Symp. Quant. Biol.},
  volume = {54},
  year = {1989},
  pages = {1--13},
}

@article{Lemaitre1996,
  author = {Lemaitre, Bruno and Nicolas, Emmanuelle and Michaut, Lydia and Reichhart, Jean-Marc and Hoffmann, Jules A.},
  title = {The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults},
  journal = {Cell},
  volume = {86},
  year = {1996},
  pages = {973--983},
}

@article{Poltorak1998,
  author = {Poltorak, Alexander and He, Xiaolong and Smirnova, Irina and Liu, Mu-Ya and Van Huffel, Christophe and Du, Xin and Birdwell, Dale and Alejos, Eva and Silva, Monica and Galanos, Chris and Freudenberg, Marina and Ricciardi-Castagnoli, Paola and Layton, Brett and Beutler, Bruce},
  title = {Defective {LPS} signaling in {C3H/HeJ} and {C57BL/10ScCr} mice: mutations in {Tlr4} gene},
  journal = {Science},
  volume = {282},
  year = {1998},
  pages = {2085--2088},
}

@article{Medzhitov1997,
  author = {Medzhitov, Ruslan and Preston-Hurlburt, Paula and Janeway, Charles A.},
  title = {A human homologue of the Drosophila Toll protein signals activation of adaptive immunity},
  journal = {Nature},
  volume = {388},
  year = {1997},
  pages = {394--397},
}

@article{Medzhitov2002,
  author = {Medzhitov, Ruslan and Janeway, Charles A.},
  title = {Decoding the patterns of self and nonself by the innate immune system},
  journal = {Science},
  volume = {296},
  year = {2002},
  pages = {298--300},
}

@article{Sun2013,
  author = {Sun, Liang and Wu, Jiaxi and Du, Fenghe and Chen, Heping and Chen, Zhijian J.},
  title = {Cyclic {GMP-AMP} synthase is a cytosolic {DNA} sensor that activates the type {I} interferon pathway},
  journal = {Science},
  volume = {339},
  year = {2013},
  pages = {786--791},
}

@article{Nelson2004,
  author = {Nelson, Alexander and Horton, C. Anthony and Lahav, Galit and White, Michael R. H.},
  title = {Oscillations in {NF-kB} signaling control the dynamics of gene expression},
  journal = {Science},
  volume = {306},
  year = {2004},
  pages = {704--708},
}

@article{Ridker2017,
  author = {Ridker, Paul M. and Everett, Brendan M. and Thuren, Tom and MacFadyen, Jean G. and Chang, Wei H. and Ballantyne, Christie and Fonseca, Felicita and Nicolau, Jose and Koenig, Wolfgang and Anker, Stefan D. and others},
  title = {Antiinflammatory therapy with canakinumab for atherosclerotic disease},
  journal = {N. Engl. J. Med.},
  volume = {377},
  year = {2017},
  pages = {1119--1131},
}

@book{Metchnikoff1901,
  author = {Metchnikoff, Elie},
  title = {L'Immunit\'{e} dans les Maladies Infectieuses},
  publisher = {Masson},
  year = {1901},
  address = {Paris},
}

@book{Janeway2017,
  author = {Janeway, Charles A. and Travers, Paul and Walport, Mark and Shlomchik, Mark},
  title = {Immunobiology},
  publisher = {Garland Science},
  year = {2017},
  edition = {9th},
}

@book{Alberts2014,
  author = {Alberts, Bruce and Johnson, Alexander and Lewis, Julian and Morgan, David and Raff, Martin and Roberts, Keith and Walter, Peter},
  title = {Molecular Biology of the Cell},
  publisher = {Garland Science},
  year = {2014},
  edition = {6th},
}